Renal graft survival and calcineurin inhibitor

Transplantation

Volumn 80, Issue 5, 2005, Pages 629-633

  Woodward, Robert S ^a   Kutinova, Andrea ^a   Schnitzler, Mark A ^b   Brennan, Daniel C ^c  

^a UNIVERSITY OF NEW HAMPSHIRE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Cyclosporine; Kidney transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FREQUENCY ANALYSIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

ADULT; CALCINEURIN; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; TACROLIMUS;

EID: 25444435958     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000184842.01686.CA     Document Type: Article

References (27)

1. Yang HC. Tailoring tacrolimus-based immunotherapy in renal transplantation. Nephrol Dial Transplant 2003; 18 Suppl 1: i16-20.
2. Sola R, Diaz JM, Guirado L, et al. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. Transplant Proc 2003; 35: 1699-1700.
3. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-1297.
4. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 2003; 63: 1535-1548.
5. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782
6. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomized multicenter study. Lancet 2002; 359; 741-746.
7. Boots JM, Van Duijnhoven EM, Christiaans MH, et al. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transplant Int 2001; 14: 370-383.
8. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-389.
9. Van Hooff JP, Christiaans MH. Use of tacrolimus in renal transplantation. Transplant Proc 1999; 31: 3298-3299.
10. Ghasemian SR, Light JA, Currier C, et al. Tacrolimus vs Neoral in renal and renal/pancreas transplantation. Clin Transplant 1999; 13: 123-125.
11. Laskow DA, Neylan JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12: 489-503.
12. Djamali A, Premasathian N, Pirsch JD. Outcomes in kidney transplantation. Sem Nephrol 2003; 23: 306-316.
13. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomized trials. Br Med J 1999; 318: 1104-1107.
14. Vanrenterghem YF. Which Calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol 1999; 8: 669-674.
15. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515-523.
16. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-975.
17. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
18. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
19. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590-598.
20. Wyzgal J, Oldakowska-Jedynak U, Paczek L, et al. Posttransplantation diabetes mellitus under calcineurin inhibitor. Transplant Proc 2003; 35: 2216-2218.
21. First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379-386.
22. United States Renal Data System (USRDS). USRDS Data CD-ROMS. Minneapolis, MN: January 2003.
23. Kahan BD, Dunn I, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511.
24. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-304.
25. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048-2053.
26. Irish WD, Sherrill B, Brennan DC, et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a tripledrug regimen. Transplantation 2003; 76: 1686-1690.
27. Orme ME, Jurewicz WA, Kumar N, McKechnie TL. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics 2003; 21: 1263-1276.